Abstract-Extracellular superoxide dismutase (EC-SOD) is a major superoxide scavenger and may be important to normal vascular function and cardiovascular health. We analyzed family data from 610 healthy Australians to detect and quantify the effects of genes on normal variation in plasma levels of EC-SOD and to test for pleiotropy with plasma nitric oxide (NO) and apolipoprotein A-I (apoA-I). Using maximum-likelihood-based variance decomposition methods, we determined that sex, age, and plasma levels of HDL cholesterol, apoA-I, and creatinine accounted for 38.6% of the variance in plasma EC-SOD levels and that additive genes accounted for 35% (PϽ0.00002). Multivariate analyses of plasma levels of EC-SOD, NO x (a measure of basal NO production), and apoA-I detected significant genetic correlations, indicating pleiotropy between EC-SOD and apoA-I (genetic correlation [ G ]ϭϪ0.45) and between NO x and apoA-I ( G ϭ0.58) but not between EC-SOD and NO x . Genes shared by EC-SOD and apoA-I account for 20% of the genetic variance and, respectively, 7% and 9% of the phenotypic variance in both traits. Shared genes also account for Ͼ33% of the genetic variance and 5% and 15% of the respective phenotypic variance in NO x and apoA-I. In healthy individuals, over a third of the variance in EC-SOD plasma levels is due to the additive effects of genes. Some genes influence EC-SOD and apoA-I levels. The same is true of NO x and apoA-I but not of EC-SOD and NO x . These patterns of pleiotropy can guide subsequent attempts to identify the genes and physiological mechanisms underlying them. 
R eactive oxygen species (ROS), such as superoxide anions, the hydroxyl radical, hydrogen peroxide, and peroxynitrites, are produced by many cell types, including endothelial cells, smooth muscle cells, neutrophils, monocytes, and platelets, 1 and are implicated in many pathologies, including those affecting the cardiovascular system. Superoxide radicals react with various molecules, resulting in either direct damage or potentially harmful products. Of particular interest to cardiovascular biology is their avid reaction with nitric oxide (NO), which is constantly produced by endothelium and facilitates the maintenance of basal vascular tone, to form peroxynitrite, a potent oxidant. [1] [2] [3] [4] Abundant peroxynitrite, as identified by nitrotyrosine, is detected in atherosclerotic lesions, and overproduction of peroxynitrite has been implicated in atherogenesis. 3, [5] [6] [7] One protective response of tissues against untoward effects of ROS is production of antioxidative molecules, such as superoxide dismutase (SOD). Whereas each of the 3 isoenzymes of SOD (secreted extracellular SOD [EC-SOD], cytosolic CuZn-SOD, and mitochondrial Mn-SOD) 8 -10 has specific cellular locations and functions, all reduce superoxide radicals to hydrogen peroxide and molecular oxygen. Over 90% of EC-SOD is found in the interstitial spaces of tissues and extracellular fluids and is responsible for the majority of SOD activity of plasma, lymph, and synovial fluid. 8, 11, 12 EC-SOD has a high affinity for heparin sulfate proteoglycans [13] [14] [15] present in the connective tissue matrix and on cell surfaces, particularly surfaces of endothelial cells. Endothelium surface-bound EC-SOD is the primary source of circulating plasma EC-SOD, and levels are in equilibrium between these 2 phases. 11, 12, 16 It is a key component in the antioxidation capability of the vascular wall and likely contributes to atherogenesis.
Results of a recent study in an Australian population with coronary artery disease are consistent with a relation between EC-SOD bioavailability and cardiovascular disease risk. 17 When individuals with a mutation known to produce extremely high EC-SOD levels were excluded, plasma EC-SOD levels were inversely associated with smoking behavior so that those of current smokers were lowest, those of exsmokers were intermediate, and those of nonsmokers were highest. Furthermore, patients with a history of myocardial infarction had lower plasma EC-SOD levels.
Known genetic effects on plasma EC-SOD levels are limited to those attributed to a single base-pair substitution, Arg2133 Gly at the heparin-binding domain, in the structural gene for EC-SOD located on chromosome 4 (4pter-q21). This mutation has been identified and found to be associated with very high plasma EC-SOD levels in several populations, albeit with a low prevalence: eg, 6% in Japanese, 3.2% in Australian whites, and 2.2% in Swedes. [17] [18] [19] [20] [21] The mutation impairs the affinity of EC-SOD for heparin at the endothelial cell surface, 18, 22, 23 but given the equilibrium between plasma and endothelial cell surface EC-SOD, it appears to be directly responsible for markedly increased plasma EC-SOD levels in those who possess it. Although it is known that the Arg2133 Gly mutation was responsible for a bimodal distribution of EC-SOD levels in the Australian study population cited above, 17 the genetic contribution to quantitative variation in the more common range of this phenotype, exhibited by 93% to 97% of that population, is still unknown.
Slightly more is known about the genetic contribution to normal variation in endothelial constitutive NO, a key molecule in peroxynitrite production against which EC-SOD is a protective response. Analyses of data from a study of healthy members of Ͼ100 Australian families showed that genes and plasma levels of apoA-I significantly influence normal variation in plasma NO levels. 24 The potential role of EC-SOD plus these observations on NO motivated the 2 principal objectives of the present study. The first was to detect and measure the effects of genes on normal quantitative variation in plasma levels of EC-SOD in individuals not possessing the Arg2133 Gly mutation. The second objective was to discern the extent to which genes influencing plasma EC-SOD levels also influenced plasma levels of NO and apoA-I.
Methods

Subjects
We collected blood samples from 610 members of 144 nuclear families, a majority of which provided the data for the earlier study in which we detected the effects of genes and apoA-I on variation in plasma NO levels. 24 Subjects were healthy volunteers recruited from the ongoing Heart Health Education Program for family-based primary coronary disease prevention. Ascertainment was random with respect to cardiovascular disease risk. All volunteers were white, of European origin, and residing in Sydney; none were current smokers. They were advised to remain on their usual diets before blood collection, and all were healthy at the time of study. Written consent was obtained from every subject and/or subject's parent. The study was approved by the Ethics Committee of the University of New South Wales.
A 4-mL venous blood sample was drawn into an EDTA tube after an overnight fast (12 to 14 hours). The blood sample was maintained at 4°C for 2 to 4 hours and centrifuged at 3500 rpm (2000g). Plasma was stored at Ϫ70°C in aliquots until analysis for EC-SOD.
Measurements of EC-SOD Levels and Biochemical Analyses
Circulating plasma EC-SOD levels were measured as described previously. 25 Plasma levels of total cholesterol, HDL cholesterol, triglycerides, glucose, and creatinine were measured by the Clinical Chemistry Department, Prince of Wales Hospital, Sydney, Australia, by using standard enzymatic methods. LDL cholesterol levels were calculated by use of the Friedewald formula. We measured levels of apoA-I, apoB, and Lp(a) by using ELISA methods developed in our laboratory. 26 Plasma NO levels (NO x , measured as the metabolites nitrite and nitrate) were assayed as described by Wang et al. 27 
Statistical Genetic Analysis
Pedigree and phenotype data management and preparation were accomplished by using the computer package PEDSYS. 28 Statistical genetic analyses were conducted with the use of maximumlikelihood methods implemented in Sequential Oliogenic Linkage Analysis Routines (SOLAR) 29 and a modified version of Pedigree Analysis Programs (PAP) 3.0 30 to compute likelihoods of genetic models on phenotypic data distributed in pedigrees.
Initial univariate analyses simultaneously estimated the mean effects of potential covariates and the proportions of the phenotypic variance in each of the 3 traits that were attributable to the additive effects of genes (heritability, or h 2 ) and unmeasured environmental factors (e 2 ). We estimated h 2 as G 2 / P 2 , where G 2 is the variance due to the effects of genes, and P 2 is the phenotypic variance. In addition to effects of sex and sex-specific age terms, we screened the following for inclusion as covariates in genetic models for each trait: plasma levels of the other 2 phenotypes, total cholesterol, HDL cholesterol, triglycerides, apoB, Lp(a), glucose, and creatinine.
Multivariate quantitative genetic analyses were conducted to determine the extent to which variation in plasma levels of EC-SOD, NO x , and apoA-I were attributable to the additive effects of shared genes and shared nongenetic factors. We used an analytical approach developed by Blangero and Konigsberg 31 and described in detail by Mahaney et al 32 to model the multivariate phenotype of an individual as a linear function of the measurements on individuals' traits, the population means of these traits, and the covariates and their regression coefficients, plus the additive genetic values and random environmental deviations. From this model, we also estimated the additive genetic and environmental (nongenetic) correlations, G and E , between trait pairs. Respectively, these 2 correlations estimate the effects of shared genes (ie, pleiotropy) and shared, unmeasured, nongenetic factors on the phenotypic variance in a trait. We used maximum-likelihood estimates of the 2 to obtain estimates of total phenotypic correlation, P , between trait pairs as described elsewhere. 32 Significance of all parameters, including variance components, covariate effects, and correlations, was assessed by natural log likelihood ratio tests, 33 in which Ϫ2ϫnatural log likelihood of a restricted model (in which the parameter value to be tested is fixed at zero) is compared with that same statistic for a more general model in which that parameter value is estimated. An additional likelihood ratio test in which the absolute value of the genetic correlation was fixed at 1.0 was used to test the hypothesis of complete pleiotropy, ie, the case for which all additive genetic variance in 2 traits is due to the same shared genes. Although critical values for including covariates in genetic models after initial screens corresponded to Pϭ0.10, we did not consider maximum estimates of, for example, heritabilities, correlations, and covariate effects to be significant in the final analyses at PϾ0.05.
Analyses of nuclear family data may lead to inflated h 2 estimates because of the confounding of additive genetic and common familial environmental effects. Spousal correlations (r sp ) were estimated for each trait, and r sp values significantly Ͼ0.0 were considered evidence of such confounding.
Results
Of the 610 participants in the present study, 300 were females (mean ages were as follows: parent and offspring generations combined, 24.1Ϯ4.9 years; parent generation, 39.0Ϯ4.8 years; and offspring generation, 10.3Ϯ3.3 years), and 310 were males (mean ages were as follows: parent and offspring generations combined, 25.5Ϯ17.0 years; parent generation, 42.5Ϯ7.8 years; and offspring generation, 10.7Ϯ3.8 years). These individuals belonged to 144 nuclear families ranging in size from 3 to 6 members, with a modal size of 4 (2 parents and 2 children). Measures of plasma EC-SOD levels were obtained for 515 individuals; NO x levels, for 550; and apoA-I levels, for 562. Data for 15 individuals (2.97% of the sample) with EC-SOD levels Ͼ700 ng/L, all of whom were determined to possess the Arg2133 Gly mutation, 20 were identified as "outliers" and eliminated from further analysis. Summary statistics for age and the 3 phenotypes for the remaining individuals in the sample, none of whom was found to have the Arg2133 Gly mutation, are presented in Table 1 .
Maximum-likelihood parameter estimates and their standard errors from the unrestricted univariate quantitative genetic model for each of the 3 traits are presented in Table  2 . In addition to age and sex terms, those covariates with potential utility for better characterization of the variance component model for each trait (ie, PϽ0.10 in the initial covariate screen) were also included. For EC-SOD, these covariates included plasma levels of HDL cholesterol, creatinine, and apoA-I and accounted for 38.6% of the phenotypic variance of this trait. Two variables, apoA-I and apoB, contributed only 6% of the phenotypic variance in NO x . Over 25% of the phenotypic variance in apoA-I was due to the effects of HDL cholesterol, triglycerides, apoB, NO x , and EC-SOD. Genes contributed significantly to the remaining residual phenotypic variance in plasma levels of EC-SOD (h 2 ϭ0.58, PϽ0.000001), NO x (h 2 ϭ0.18, Pϭ0.000016), and apoA-I (h 2 ϭ0.62, PϽ0.000001). Respectively, these estimates indicate that additive genetic effects account for 35.6%, 16.7%, and 15.7% of the total phenotypic variance in EC-SOD, NO x , and apoA-I. Because no r sp value was significantly Ͼ0.0 (SOD r sp ϭϪ0.03, NO x r sp ϭϪ0.02, and apoA-I r sp ϭ0.06; PϾ0.10), inflation of the heritability estimates due to common familial environmental effects is unlikely in these data.
Using parameter estimates from Table 2 as the new initial values, we maximized the likelihood of a single trivariate quantitative genetic model that included plasma EC-SOD, NO x , and apoA-I on the same family data to estimate genetic and nongenetic correlations between these traits (note that because they were included as the primary phenotypes in this trivariate model, plasma levels for these 3 traits were not included also as covariates). Maximum-likelihood estimates of the correlations due to shared effects of additive genes and shared effects of nongenetic factors and the phenotypic correlations derived from them are presented in Table 3 . Plasma levels of EC-SOD exhibit a significant negative genetic correlation with apoA-I levels only ( G ϭϪ0.45). In contrast, plasma apoA-I levels show a significant, but positive, genetic correlation with plasma levels of NO x ( G ϭ0.58). Likelihood ratio tests rejected the hypothesis of complete pleiotropy for both significant correlations (PϽ0.05). None of the correlations due to unmeasured nongenetic factors was significant (PϾ0.09).
The squared additive genetic correlation is interpreted as the proportion of the additive genetic variance in each of the 2 traits attributable to shared genetic effects (Table 4) . Shared genetic effects account for Ϸ20% of the additive genetic variance in plasma levels of EC-SOD and apoA-I. NO x and apoA-I share nearly 34% of their additive genetic effects. Similar treatment of the nonsignificant correlations between EC-SOD and NO x reveals that shared genetic effects would account for Ͻ3% of the additive genetic variance in these 2 traits.
The proportion of the total phenotypic variance in each trait of a trait pair that is due to the effects of shared genes equals the product of the squared additive genetic correlation, h 2 , and the proportion of the total phenotypic variance not attributable to covariate effects. For EC-SOD and NO x , these proportions are negligible; but for EC-SOD and apoA-I, respectively, the proportions of the total phenotypic variance due to shared gene effects are 7.2% and 9.3%; and, for NO x and apoA-I, the respective proportions are 5.7% and 15.5%.
Analogous calculations applied to correlations due to shared, unmeasured, nongenetic factors provides tentative evidence for such an effect between plasma levels of EC-SOD and apoA-I only. Shared unmeasured nongenetic factors account for Ͻ1% of the total phenotypic variance in either of these 2 traits.
Discussion
Because plasma EC-SOD levels have been shown to be correlated with history of cardiovascular disease and its risk factors, 17 genes influencing quantitative variation in plasma EC-SOD levels are likely to contribute also to interindividual variance in cardiovascular disease susceptibility. To our knowledge, this is the first reported quantification of the effect of genes on normal quantitative variation in plasma levels of EC-SOD in this or any other population. We have learned that Ͼ35% of the total phenotypic variance in circulating plasma levels of EC-SOD is attributable to the effects of genes other than 1 previously described mutation. 17 Although obtained from analysis of data from nuclear families, our finding of a nonsignificant spousal correlation suggests that the magnitude of this estimated genetic effect is unlikely to be inflated by common familial environmental factors. This is true also for the NO x and apoA-I heritability estimates and for the correlations obtained in subsequent multivariate analyses.
To our knowledge, little is known of the possible interactions of growth, development, and maturation on differences in plasma EC-SOD levels in children, adolescents, and adults. 34 If they existed, such interactions might tend to obscure, rather than inflate, evidence of additive genetic effects on variation in a sample like ours, in which the data from both adults in the parental generation and their preadult offspring were analyzed. Consequently, we are confident that the estimates of heritability and genetic correlation presented in the present study are, at worst, conservative ones.
Contrary to our expectations, given the reported concordance between EC-SOD expression and inducible NO synthase expression in human and rabbit atherosclerotic lesions, 35 we have also learned that in these Australian families EC-SOD levels are related to NO x levels through their separate pleiotropic interactions with plasma levels of apoA-I. Significant positive pleiotropy between apoA-I and NO x indicates that a common gene or suite of genes contributes to correlated upregulation and downregulation of production for both phenotypes. We believe that this pleiotropy is biologically important: over a third of the additive genetic variance in both traits and nearly 16% and 6% of the total phenotypic variance in apoA-I and NO x , respectively, are attributable to the additive effects of the same gene or genes. Because the pleiotropy is incomplete, other genes, not shared by these 2 traits, account for Ͼ60% of the additive genetic variance in these 2 traits.
EC-SOD and apoA-I also share genes in common, but this pleiotropic relation is a negative one. When mechanisms that influence plasma levels of EC-SOD are upregulated, those influencing plasma levels of apoA-I are downregulated, or vice versa. This pleiotropy is somewhat weaker than that between plasma levels of NO x and apoA-I, accounting for one fifth of the additive genetic variance in plasma EC-SOD and apoA-I levels and Ϸ7% and 9% of their respective total phenotypic variance. Genes other than those producing this negative pleiotropy are responsible for the remaining additive genetic variance in plasma levels of EC-SOD and apoA-I. A lack of pleiotropy between EC-SOD and NO x when both exhibit pleiotropy with apoA-I indicates that the 2 observed pleiotropic relations (EC-SOD with apoA-I and NO x with apoA-I) are attributable to 2 independent sets of genes. However, our findings are from analyses of data obtained from healthy families with no frank cardiovascular disease and the correlated expression of EC-SOD and inducible NOS, leading us to expect the pleiotropy between EC-SOD and NO x that was observed in studies of atherosclerotic lesions. 33 It is possible that interaction with internal or external environmental factors, normal or pathological, that are not present in the families in the present study could effect the gene expression necessary to establish this "missing" pleiotropy.
It is highly unlikely that the genetic correlations detected in the present study are reflective of linkage rather than pleiotropy. That would require strong linkage disequilibrium resulting from multiple mutations at different loci within a very narrow region (eg, ϽϽ1 cM) of a chromosome.
The ultimate objective of any cardiovascular disease genetics research includes the unambiguous identification and complete characterization of the individual genes responsible for quantitative variation in a risk factor for, or susceptibility to, cardiovascular disease. The present study does not identify the specific loci responsible for our observations, but quantifying the extent to which variation in EC-SOD is heritable is a necessary prerequisite to initiating a formal search for those loci (ie, one cannot localize and identify genes for traits having no measurable genetic component). Whereas statistical power to localize and identify the actual loci involved is proportional to the effect size (ie, heritability) of those loci, 29 this power can also be improved greatly by exploiting the pleiotropy observed between these phenotypes in a multivariate whole genome linkage screen. 36 -38 At this time, obvious candidate genes include structural loci for the 3 traits and/or loci whose products are thought to be central to regulating their production: eg, apoAI at 11q23, ecNOS at 7q35 to 36, iNOS at 17cen-q12, and ecSOD at 4pter-q21. One or more of these loci may contribute to the detected pleiotropy. The previously noted effect of the dominant-acting Arg2133 Gly mutation in the ecSOD locus on plasma levels of EC-SOD 17 and linkage of ecNOS4 genotypes to variation in NO x levels in many of these same families lend credence to this possibility. 24 However, it is just as likely that other loci, including those that currently may be unknown and/or whose effects on one or more of these traits has yet to be appreciated, also are involved.
The actual regulatory mechanisms responsible for these pleiotropic relations remain speculative. A possible role for apoA-I may derive from recent reports that it is readily oxidizable in vitro. 39, 40 Although in vivo apoA-I oxidation remains to be demonstrated, a recent study suggests that compared with native apoA-I, oxidized apoA-I may promote more efficient reverse cholesterol transport. 41 Therefore, a possible functional link between apoA-I and NO and between apoA-I and EC-SOD is a scenario casting apoA-I as an antioxidant or ROS recipient whereby overproduction of NO might necessitate increased apoA-I production to counter the untoward oxidation effect.
In summary, genes influence a significant proportion of the quantitative phenotypic variation in plasma levels of EC-SOD in healthy Australians. Some, but not all, of these genes also contribute significantly to variation in plasma levels of apoA-I but not NO x . Although a small, but significant, proportion of normal variation in plasma levels of NO x is attributable to the effects of genes that also influence variation in plasma apoA-I levels, these genes, or their effects, are not shared with plasma EC-SOD. Given the hypothesized importance of mechanisms that counter ROS to the maintenance of healthy endothelial function and prevention or amelioration of cardiovascular disease, 42 our results warrant further studies. The objectives of these studies should include localizing and identifying the genes responsible for this pleiotropy in healthy individuals, determining whether it is maintained in the presence of cardiovascular disease and/or exposure to pathological levels of other known risk factors, and investigating its possible physiological bases.
